Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Furosemide for COVID-19 Pulmonary Inflammation
NCT04588792Phase 3Terminated
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of furosemide in coronavirus disease 2019 (COVID-19) and respiratory failure (2 arms). Primary endpoints: Improvement in pulmonary gas exchange at Day 6 and Requirement for mechanical ventilation. Started Apr 2021; status: terminated.
02
Drugs
furosemide
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failure
Beyond the preview
Go deeper on NCT04588792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588792.